Diagnosis: Mycosis fungoides, tumor stage
A 62-year-old male presents with multiple ulcerated tumors arising on pre-existing patches of skin. The lesions have progressively enlarged over the past year, causing significant discomfort and concern. Upon examination, the patient exhibits several infiltrated plaques and nodules, prompting further investigation into a potential hematologic malignancy.
The patient is a 62-year-old male with a one-year history of multiple ulcerated tumors on his trunk and extremities. He reports that these lesions have been progressively enlarging and causing discomfort. Physical examination reveals several well-defined, infiltrated plaques and ulcerated nodules predominantly on the trunk. There are also erythematous patches scattered on the extremities, with some areas exhibiting exudation.Age: 62 yearsSex: MaleDuration: One yearKey complaint: Multiple ulcerated tumorsExam findings: Infiltrated plaques and nodules
The patient reports that the skin lesions began as small, itchy patches that gradually expanded over the year. He has a history of chronic eczema and was previously treated with topical corticosteroids without significant improvement. There are no known triggers, although he notes increased stress during the past year. The patient has no significant past medical history and denies any family history of skin cancer or hematologic malignancy. He is a retired landscaper and has had significant sun exposure throughout his life.Onset: One year ago with small patches.Prior treatments: Topical corticosteroids without improvement.Relevant history: Chronic eczema.Family history: No skin cancer or hematologic malignancy.Occupational exposure: Significant sun exposure.
Acute / First-Line ManagementConsider topical chemotherapy with carmustine 0.7% applied to affected areas daily for 5 days per week.In cases of extensive disease, initiate systemic therapy with methotrexate at a dose of 15-25 mg weekly, adjusting as tolerated.Phototherapy with narrowband UVB can be utilized, typically 2-3 times per week.Assess for radiation therapy for localized ulcerated tumors if symptomatic.Workup and Diagnostic ConfirmationPerform a skin biopsy for histopathological examination to confirm the diagnosis.Consider immunophenotyping of the biopsy sample to assess for atypical T-cells.Conduct a CT scan of the chest, abdomen, and pelvis to evaluate for lymphadenopathy and staging.Check blood counts and lactate dehydrogenase (LDH) levels as part of the workup.Long-Term ManagementMonitor regularly for disease progression and response to therapy.Consider retinoids such as bexarotene at a dose of 300 mg/m²/day for systemic management if indicated.Evaluate for clinical trials involving novel therapies if appropriate.Maintain open communication regarding psychosocial support and management of treatment side effects.
Psoriasis: Characterized by silvery scales and well-defined borders; typically presents with less induration compared to the lesions described.Cutaneous T-cell lymphoma (CTCL): Includes a spectrum of lymphoproliferative disorders; consider in patients presenting with infiltrated patches and plaques.Granuloma annulare: Presents with annular plaques without significant ulceration; often self-limiting and not typically associated with systemic symptoms.Basal cell carcinoma: Common skin cancer that may present as ulcerated lesions, but typically has a pearly appearance and less induration.Keratoacanthoma: Rapidly growing crateriform lesions that may resemble squamous cell carcinoma; usually self-limiting.Secondary syphilis: May present with ulcerated lesions; however, associated systemic symptoms and serologic testing will aid in differentiation.Vasculitis: Can cause ulcerated lesions, often with systemic symptoms and specific laboratory findings.Leukemia cutis: Associated with systemic hematologic malignancies; lesions may be infiltrative and associated with systemic disease.
High-Yield PearlsStaging: Mycosis fungoides is staged based on the extent of skin involvement and presence of lymphadenopathy or systemic disease, as outlined by Olsen et al.Histopathology: A definitive diagnosis relies on histological examination, revealing atypical lymphocytes in the epidermis and/or dermis.Management: Treatment approaches vary from topical therapies for early-stage disease to systemic therapies for advanced stages.Monitoring: Regular follow-up is crucial for early detection of disease progression and treatment response.Multidisciplinary care: Involving dermatologists, oncologists, and palliative care specialists is essential for optimal management.Early recognition and appropriate staging of mycosis fungoides are critical for effective treatment and improved patient outcomes.
Tags: mycosis fungoides, tumor stage, CTCL